<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577509</url>
  </required_header>
  <id_info>
    <org_study_id>LXMSB201701/PRO</org_study_id>
    <nct_id>NCT03577509</nct_id>
  </id_info>
  <brief_title>Single Dose Escalations Study of Amphotericin B Colloidal Dispersion In Healthy Subjects in China</brief_title>
  <official_title>Pharmacokinetics, Safety and Tolerability of Single Infusion of Amphotericin B Colloidal Dispersion In Healthy Subjects in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the pharmacokinetics of single intravenous of
      Amphotericin B Colloidal Dispersion(ABCD)in Chinese healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: Evaluation the pharmacokinetics, safety and tolerability of single
      intravenous of ABCD in Chinese healthy subjects.

      Secondary Objective: Evaluation the safety and tolerability of single intravenous of ABCD in
      Chinese healthy subjects.

      Exploratory Objective:Evaluation the effect of single intravenous ABCD on early renal injury
      indicators (KIM-1 and cystatin C) in Chinese healthy subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2, 2018</start_date>
  <completion_date type="Actual">September 14, 2018</completion_date>
  <primary_completion_date type="Actual">September 14, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of single infusion of ABCD</measure>
    <time_frame>before infusion and at the midpoint and end of the infusion;and at 15 and 30 min;1,2,4,7,10,24,48,72,120,168,240,336,408,504,576 and 672hour postinfusion</time_frame>
    <description>Peak Plasma Concentration,.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of single infusion of ABCD</measure>
    <time_frame>before infusion and at the midpoint and end of the infusion;and at 15 and 30 min;1,2,4,7,10,24,48,72,120,168,240,336,408,504,576 and 672hour postinfusion</time_frame>
    <description>Area under the plasma concentration versus time curve</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Invasive Fungal Disease</condition>
  <arm_group>
    <arm_group_label>ABCD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group1: 0.5mg/kg Group2: 1.0mg/kg Group3: 1.5mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABCD</intervention_name>
    <description>Intravenous infusion of dexamethasone 5mg before ABCD intravenous administration; Single infusion.</description>
    <arm_group_label>ABCD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) of 19 to 26 kg/m2, inclusive 19 and 26. BMI = weight
             (kg)/[height(m)]2.

          -  Subjects are fully informed and voluntarily consent to participate in this study.

        Exclusion Criteria:

          -  History of allergy or hypersensitivity.

          -  Presence of any acute or chronic medical condition within 3 months prior to
             investigational products administration, including but not limited to: hepatic,
             gastrointestinal, renal, hematologic (including coagulation), pulmonary, neurologic,
             respiratory, endocrine, or cardiovascular system abnormalities; psychiatrical disease
             including major psychiatric disorders (e.g., schizophrenia, bipolar disorder); acute
             infection; or other conditions that would interfere with the absorption, distribution,
             metabolism, or excretion of drugs.

          -  During the screening period, abnormal and clinically significant of physical
             examination, vital signs, laboratory examination, etc.

          -  A positive result in hepatitis B surface antigen (HBsAg), hepatitis B e antigen
             (HBeAg), anti-hepatitis C virus (HCV) antibodies, a syphilis test, or an human
             immunodeficiency virus (HIV) test.

          -  Lost blood or donated more than 400 mL of blood within 3 months prior to the
             screening.

          -  Participation in a clinical drug study 30 days prior to present study.

          -  Use of any other drugs within 2 weeks prior to the screening.

          -  Subjects planning to give birth or donate sperm during the study or within 3 months
             after the study.

          -  The partner of the subject is unwilling to take effective contraceptive measures.

          -  Other unfavorable factors diagnosed by investigators.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Zhang, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huashan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 28, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>October 7, 2018</last_update_submitted>
  <last_update_submitted_qc>October 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

